Eli Lilly Trial Shows High Weight Loss for Drug Combo, but Also High Dropout Rates
A recent trial from Eli Lilly combining tirzepatide with experimental drug eloralintide showed significant weight loss, but came with a high 27% discontinuation rate.
A recent trial from Eli Lilly combining tirzepatide with experimental drug eloralintide showed significant weight loss, but came with a high 27% discontinuation rate.